New Thrombotic Events in Ischemic Stroke Patients with Elevated Factor VIII
Table 3
Baseline characteristics of patients with and without an in-hospital thrombotic event.
Any new thrombotic event ( = 46)
No new thrombotic event ( = 252)
value
FVIII level, median IU/mL (range)
2.14 (0.67–6.08)
1.71 (0.72–5.14)
0.0003
Age, median (range)
54 (19–90)
54 (21–85)
0.5778
Gender, % female
26 (56.5%)
125 (49.6%)
0.3881
Black race, %
35 (76.1%)
180 (71.4%)
0.5169
Past medical history, %
Coronary artery disease
8 (17.4%)
56 (22.2%)
0.4631
Diabetes
15 (33.3%)
84 (33.6%)
0.9722
Hypertension
33 (75%)
187 (74.2%)
0.9115
Dyslipidemia
14 (31.8%)
87 (34.5%)
0.7269
Atrial fibrillation
2 (4.5%)
7 (2.8%)
0.5320
Stroke
17 (37%)
103 (40.9%)
0.0594
Cancer
6 (13.3%)
13 (5.2%)
0.0390
Baseline NIHSS, median (range)
5 (0–24)
5 (0–33)
0.1611
Baseline laboratory values
Glucose, median mmol/L (range)
6.94 (3.89–22.53)
6.37 (3.22–46.12)
0.3710
INR
1.0 (0.9–2.5)
1.0 (0.7–3.8)
0.1310
IV tPA, %
12 (26.1%)
94 (37.3%)
0.1440
Active smoker, %
14 (31.8)
98 (39.4)
0.3428
Home medications, %
Any antithrombotic
14 (30.4%)
93 (36.9%)
0.4003
Any antiplatelet
13 (28.9%)
88 (35.3%)
0.4016
Any anticoagulant
1 (2.4%)
8 (3.4%)
0.7398
TOAST, %
0.0014
Cardioembolic
6 (13%)
44 (18%)
Large vessel disease
12 (26.1%)
36 (14.8%)
Small vessel disease
1 (2.2%)
34 (13.9%)
Cryptogenic (>1 cause)
9 (19.6%)
75 (30.7%)
Cryptogenic (no cause found)
8 (17.4%)
11 (4.5%)
Other
10 (21.7%)
44 (18%)
NIHSS indicates National Institutes of Health Stroke Scale; IQR, interquartile range; INR, international normalized ratio; IV tPA, intravenous tissue plasminogen activator; TOAST, trial of ORG 10172 in Acute Stroke Treatment; DVT ppx, deep vein thrombosis prophylaxis.
